<DOC>
	<DOC>NCT01346215</DOC>
	<brief_summary>The purpose of this study is to investigate clinical non-inferiority, pharmacodynamic effect and safety of Actparin® (heparin sodium - Laboratório Químico Farmacêutico Bergamo Ltd.) compared to Heparin Sodium (APP Pharmaceuticals) in patients with renal failure under hemodialysis treatment.</brief_summary>
	<brief_title>Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Patients research that agree to participate in the study and sign the informed consent form; Patients aged over 18 years, both sexes, regardless of color or social class; Patients with impaired renal function in chronic hemodialysis schedule of at least 3 times a week and giving the use of heparin in the prophylaxis of thrombosis in the system; Patients with laboratory results within specified acceptance criteria. Patients who are taking part or took part in another clinical investigational study within 12 months; Hypersensitivity to heparin sodium and/or benzyl alcohol; History of active hemorrhage with alteration of blood coagulation, such as genetic disorders of coagulation system; History of disease that could aggravate or terminate the clinical manifestations, such as active peptic or gastric ulcer; Severe liver disease; Patients in cancer treatment; Pregnant and lactating women; Use of glucocorticoids over physiological dose; Use of other anticoagulants; Patients undergoing any surgery performed less than 15 days; History of non response or exacerbated response to heparin sodium; Patients who do not adapt to 150 UI/kg dose.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>heparin</keyword>
	<keyword>renal insufficiency, chronic</keyword>
	<keyword>extracorporeal dialysis</keyword>
	<keyword>fibrinolytic agents</keyword>
	<keyword>anticoagulants</keyword>
	<keyword>aPTT</keyword>
</DOC>